The global artificial intelligence for drug discovery and development market size was valued at USD 2.4 billion in 2025 and is projected to grow from USD 3.12 billion in 2026 to USD 25.28 billion by 2034, registering a CAGR of 29.9% during the forecast period from 2026 to 2034. North America dominated the artificial intelligence for drug discovery and development market with a market share of 41.5% in 2025.
Artificial intelligence for drug discovery and development involves using AI technologies such as machine learning and deep learning to identify drug candidates, predict their properties, optimize compounds, and support clinical research. It helps pharmaceutical and biotechnology companies reduce development time, improve research accuracy, and lower costs. Adoption is growing due to increasing R&D investments, large biomedical datasets, and demand for faster and more efficient drug development.
Download a Free Sample To learn more about this report,
Increasing Adoption of Generative AI for Molecular and Drug Design
The artificial intelligence for drug discovery and development market is increasingly adopting generative AI technologies to support the creation and optimization of novel molecular structures. These systems can analyze chemical and biological information to generate potential drug candidates with selected characteristics. Pharmaceutical and biotechnology companies are incorporating generative models into early-stage discovery workflows to improve candidate design and accelerate molecular optimization.
In March 2025, pharmaceutical and AI-focused biotechnology companies continued advancing generative AI platforms for molecular design and early-stage drug discovery.
Growing Integration of Multimodal AI Across Drug Research Workflows
AI platforms are increasingly being developed to analyze and combine different forms of biomedical information, including genomic data, scientific literature, clinical information, molecular data, and experimental results. This integration enables researchers to examine complex relationships across multiple datasets and generate broader insights into disease mechanisms and therapeutic targets. The trend is expanding AI adoption from individual discovery tasks toward more connected research workflows.
In August 2025, advances in multimodal AI continued supporting the integration and analysis of complex biological and biomedical datasets across pharmaceutical research activities.
Rising Drug Development Costs Increase Demand for Research Efficiency
Conventional drug discovery and development requires substantial investment in laboratory research, preclinical studies, clinical trials, and regulatory activities. High development costs and the risk of candidate failure are encouraging pharmaceutical companies to adopt technologies that can improve research efficiency and prioritize promising programs. AI can support faster analysis and better-informed decision-making, making the need to improve R&D productivity a major market driver.
In April 2025, pharmaceutical companies continued increasing investment in AI-enabled technologies to improve research productivity and optimize drug development processes.
Limited Availability of High-Quality and Standardized Biological Data
AI models depend on reliable and well-structured datasets, but biological and clinical information is often fragmented across institutions, research systems, and data formats. Differences in experimental methodologies, patient populations, and laboratory procedures can affect data consistency and limit model performance. These data-quality and interoperability issues can therefore restrict the scalability and reliability of AI-driven drug discovery platforms.
In June 2025, data standardization and interoperability remained important considerations affecting the implementation of AI technologies across biomedical and pharmaceutical research.
Expansion of AI Applications in Clinical Trial Development
AI creates growth opportunities beyond early-stage drug discovery by supporting clinical trial planning, patient identification, site selection, and operational decision-making. Advanced analytical systems can help researchers identify appropriate patient populations and improve the efficiency of clinical development activities. The growing need to optimize clinical trial execution is therefore creating new opportunities for AI technology providers.
In September 2025, pharmaceutical and technology companies continued developing AI-enabled solutions designed to improve clinical trial planning, patient identification, and operational workflows.
Regulatory Validation and Transparency of AI-Generated Insights
AI-generated predictions and recommendations must be sufficiently reliable, reproducible, and understandable to support scientific and development decisions. Complex algorithms can create challenges when researchers or regulators need to understand how a particular output was generated. Establishing robust validation processes, appropriate governance frameworks, and transparent documentation therefore remains a significant challenge for companies applying AI across drug discovery and development.
In November 2025, regulatory and industry discussions continued emphasizing transparency, validation, reproducibility, and governance for AI systems used in scientific and healthcare-related applications.
Drug Optimisation and Repurposing Segment Dominated the Market with 47.6% Share in 2025
The drug optimisation and repurposing segment dominated the global artificial intelligence for drug discovery and development market with a 47.6% share in 2025. AI technologies help researchers analyze large datasets, identify promising drug candidates, predict molecular interactions, and discover new therapeutic uses for existing drugs. These capabilities can reduce development time and improve the efficiency of drug research, supporting the segment's leading position.
The preclinical testing segment is also growing rapidly as AI models are increasingly used to predict drug toxicity, efficacy, and biological responses before clinical trials. The others segment continues to expand through applications such as target identification, molecular design, and clinical research support. Increasing adoption of AI across pharmaceutical R&D is expected to support all application segments.
Request Customizationto receive a tailored report.
Oncology Segment Dominated the Market with 38.7% Share in 2025
The oncology segment dominated the global artificial intelligence for drug discovery and development market with a 38.7% share in 2025. AI is increasingly used in cancer research to identify therapeutic targets, analyze complex biological data, discover drug candidates, and support the development of precision treatments. Strong investment in oncology research and growing demand for targeted therapies continue to strengthen the segment's leading position.
The neurodegenerative diseases segment is also witnessing strong growth as researchers use AI to study complex conditions and identify potential treatments for neurological disorders. Infectious disease applications continue to expand as AI helps analyze pathogens, identify drug targets, and accelerate therapeutic discovery.
The others segment also contributes through research across cardiovascular, metabolic, autoimmune, and rare diseases. Expanding AI capabilities are expected to support drug discovery across all therapeutic areas.
Pharmaceutical & Biotechnology Segment Dominated the Market with 61.8% Share in 2025
The pharmaceutical & biotechnology segment dominated the global artificial intelligence for drug discovery and development market with a 61.8% share in 2025. Pharmaceutical and biotechnology companies increasingly integrate AI into research workflows to improve target identification, optimize compounds, analyze biological data, and reduce the time required for drug development. Growing investment in AI-powered research platforms continues to support the segment's leading position.
The CRO segment is also expanding rapidly as pharmaceutical companies increasingly outsource research activities to organizations with specialized AI capabilities and drug development expertise. AI-enabled CRO services can support candidate screening, preclinical research, data analysis, and other development activities.
The others segment continues to grow through adoption among academic institutions, research organizations, and specialized technology providers. Increasing collaboration between life sciences companies and AI developers is expected to support long-term growth across all end-use segments.
Speak to an Analystto discuss market opportunities.
North America artificial intelligence for drug discovery and development market accounted for 41.5% of the global market, reaching USD 1.00 billion in 2025, and is projected to grow at a CAGR of 28.9% during the forecast period. Strong pharmaceutical and biotechnology research, increasing investment in AI-based drug development platforms, and growing collaboration between technology companies and drug manufacturers are supporting regional growth. AI is increasingly being used to identify drug targets, optimize compounds, and shorten development timelines.
The US market was valued at USD 0.85 billion in 2025, making it the largest contributor in North America. Strong biotechnology investment, widespread adoption of AI in pharmaceutical R&D, and increasing partnerships between technology and life sciences companies continue to support market growth.
Canada's market reached USD 0.15 billion in 2025. Growing AI research capabilities, expanding biotechnology activities, and increasing investment in computational drug discovery are supporting market development.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe artificial intelligence for drug discovery and development market accounted for 27.2% of the global market, reaching USD 0.65 billion in 2025, and is expected to register a CAGR of 27.8% during the forecast period. Strong pharmaceutical research, increasing adoption of machine learning in drug development, and growing investment in computational biology are supporting market expansion. Research institutions and pharmaceutical companies are increasingly collaborating to accelerate the identification and development of new therapies.
Germany's market accounted for USD 0.19 billion in 2025. A strong pharmaceutical and biotechnology sector, increasing AI research, and growing investment in digital drug development technologies continue to support market growth.
The UK market was valued at USD 0.13 billion in 2025. Strong life sciences research, a growing AI ecosystem, and increasing collaboration between biotechnology companies and research institutions continue to contribute to market expansion.
Asia Pacific artificial intelligence for drug discovery and development market accounted for 21.8% of the global market, valued at USD 0.52 billion in 2025, and is projected to register a CAGR of 32.4% during the forecast period. Rapid expansion of pharmaceutical research, increasing investment in artificial intelligence, and growing availability of healthcare and genomic data are driving regional growth. Pharmaceutical companies are increasingly adopting AI tools to improve drug screening, target identification, and clinical development.
Japan's market generated USD 0.09 billion in 2025. Strong pharmaceutical research capabilities, increasing adoption of AI technologies, and growing investment in advanced drug discovery platforms continue to support market growth.
China's market accounted for USD 0.27 billion in 2025, making it a major contributor within Asia Pacific. Rapid growth of biotechnology companies, increasing AI investment, and expanding pharmaceutical R&D activities continue to drive market development.
Middle East & Africa artificial intelligence for drug discovery and development market accounted for 4.2% of the global market, reaching USD 0.10 billion in 2025, and is anticipated to grow at a CAGR of 25.4% during the forecast period. Increasing investment in healthcare technology, expanding artificial intelligence capabilities, and growing interest in pharmaceutical research are supporting market development across the region.
The UAE market was valued at USD 0.04 billion in 2025. Increasing investment in artificial intelligence, healthcare innovation, biotechnology research, and digital health infrastructure continues to support the adoption of AI-based drug discovery technologies.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
AI in Radiology Market Size, Share, Growth, Analysis, Report, 2034
Ablation Technology Market Size, Share, Growth, Analysis, 2034
Machine-to-Machine (M2M) Healthcare Market Size, Share, 2034
Healthcare Digital Signage Market Size, Share, Growth, Analysis, 2034
Wireless Brain Sensors Market Size, Share, Growth, Analysis, 2034
Telepharmacy Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com